Better Access Better Healthcare
We improve global healthcare through better access to medicine.
Abacus Medicine is firmly established among the market leaders in the European parallel distribution industry.
Abacus Medicine Clinical Trial Services provides comparator sourcing services to support the running of clinical trials for pharma companies.
Abacus Medicine Pharma Services provides end-to-end commercialisation services to advance access to rare disease medicines in Europe.
Originalis is a parallel distributor of medicine operating in Germany and Ireland, providing customers with more options to choose from.
Pluripharm is a leading wholesaler in the Netherlands and offers a full line of medicines, medical devices and services to a range of customers.
We are innovative, dedicated
and we care.
The Abacus Medicine Group is built on a strong purpose. When we compete in the market, we help lower the prices on life-critical medicines so that they become more widely available.
The Abacus Medicine Group is a business. We operate commercially, and our activities provide jobs, careers and livelihoods for hundreds of people in dozens of countries.
But we are more than that. When we compete in the market, we help life-critical medicines become more widely available. This gives us a purpose beyond ourselves and is something we can be proud of.
Flemming Wagner
CEO & majority shareholder
Global locations
Employees
Packs sold in 2023
A career in the Abacus Medicine Group
Join an ambitious and diverse company.
We are always looking for new and dedicated colleagues.
Latest news
The Abacus Medicine Group Today Announces the Nomination of Two New Members of The Board of Directors
Alette Verbeek and Sharon Curran are being nominated by the main shareholders, Wagner Family Holding ApS (approx. 58% ownership) and Chr. Augustinus Fabrikker Aktieselskab (approx. 35% ownership). All shareholders have been invited to an extraordinary general meeting on 4th October, 2024.
Celebrating 20 Years of Success
The Abacus Medicine Group celebrates its 20th anniversary. We have experienced a fantastic development through 20 years of uninterrupted growth. With your help, we have grown into one of the 100 largest companies in Denmark, and have been the only Danish company to receive 12 gazelles from Børsen.
Abacus Medicine Pharma Services and Mirum Pharmaceuticals sign partnership agreement for the commercialization of Livmarli® in the Nordics
Under the terms of the agreement, Mirum Pharmaceuticals has appointed Abacus Medicine Pharma Services to exclusively promote, market, sell, distribute, and commercialize LIVMARLI in the territory of Denmark, Finland, Iceland, Norway, and Sweden.
